Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169515 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT05169515: Recruiting Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche.
NCT05169515 is a Phase 1 study of Non-Hodgkin Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 121 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05169515, a Phase 1 study of Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Iberdomide
- DRUG Golcadomide
- DRUG SC Mosunetuzumab
- DRUG IV Glofitamab
Study Locations (20)
Other
- Soroka - Beersheba
- Rambam Health Care Campus - Haifa
- Hadassah University Hospital - Ein Kerem - Jerusalem
- Center Hospital - Ramat Gan
- Sourasky Medical Center - Tel Aviv
- Hospital Universitari Vall d Hebron - Barcelona
- Clinica Universidad de Navarra-Madrid - Madrid
Emilia-Romagna
- IRCCS Azienda Ospedaliero Universitaria di Bologna - Bologna
- IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori" - Meldola
Lombardy
- ASST Spedali Civili di Brescia - Brescia
- Irccs Ospedale San Raffaele - Milan
California
- UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program - San Francisco
Colorado
- University of Colorado - Aurora
Florida
- Moffitt Cancer Center - Tampa
Illinois
- The University of Chicago - Chicago
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2029-09-15 |
| Phase | Phase 1 |
What NCT05169515 shows while recruiting
NCT05169515 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT05169515 names 20 study sites across 12 states, led by Other, Emilia-Romagna, Lombardy.
Frequently Asked Questions
What is clinical trial NCT05169515 about?
NCT05169515 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma". This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
What is the current status of trial NCT05169515?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2022-10-26. Estimated completion is 2029-09-15.
What conditions does trial NCT05169515 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05169515?
The interventions under investigation include: Obinutuzumab (DRUG), Iberdomide (DRUG), Golcadomide (DRUG), SC Mosunetuzumab (DRUG), IV Glofitamab (DRUG).
Who is sponsoring clinical trial NCT05169515?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05169515 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05169515's enrollment target sits among peer trials
121 30th of 106 higher than 77 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05488431 · 121 participants · Phase 2
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI